Product Description
Mechanisms of Action: RR Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Brain Cancer
Phase 2: Non-Small-Cell Lung Cancer|Glioblastoma|Brain Stem Cancer|Renal Cell Carcinoma|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Glioma|Multiple Myeloma|Melanoma|Brain Cancer|Lymphoma, Non-Hodgkin|Breast Cancer|Adenocarcinoma|Gliosarcoma
Phase 1: Breast Cancer|Astrocytoma|Oligodendroglioma|Prostate Cancer|Glioblastoma|Head and Neck Cancer|Plasmacytoma|Myelodysplastic-Myeloproliferative Diseases|Gastrointestinal Cancer|Intestinal Cancer|Lung Cancer|Breast Diseases|Leukemia, Plasma Cell|Multiple Myeloma|Prostatic Diseases|Colorectal Cancer|Myeloproliferative Disorders|Lymphoma|Bronchogenic Carcinoma|Hypopharyngeal Cancer|Oropharyngeal Cancer|Squamous Cell Carcinoma|Non-Small-Cell Lung Cancer|Glioma|Intestinal Diseases|Rectal Diseases|Laryngeal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| A6701QIBA | N/A |
Unknown status |
Prostate Cancer |
2022-12-01 |
2023-08-03 |
Primary Endpoints|Treatments|Trial Status |
|
| NCI-2012-02607 | N/A |
Terminated |
Gallbladder Cancer|Soft Tissue Cancer|Ovarian Cancer|Fallopian Tube Cancer|Embryonal Carcinoma|Leiomyosarcoma|Peritoneal Cancer|Bile Duct Cancer|Adenocarcinoma|Non-Small-Cell Lung Cancer|Colorectal Cancer|Carcinoid Tumor|Lymphoma|Gastrointestinal Cancer|Pancreatic Cancer|Appendiceal Cancer|Malignant Carcinoid Syndrome|Liver Cancer|Germinoma|Gastrointestinal Stromal Tumors|Cholangiocarcinoma|Uterine Cancer |
2006-01-01 |
2019-03-22 |
Treatments |
|
| NCI-2012-01845 | P1 |
Completed |
Glioma |
2007-03-01 |
2019-03-21 |
Treatments |
|
| CDR0000069322 | P1 |
Completed |
Myeloproliferative Disorders|Lymphoma|Rectal Diseases|Intestinal Diseases|Head and Neck Cancer|Colorectal Cancer|Intestinal Cancer|Plasmacytoma|Prostatic Diseases|Breast Cancer|Leukemia, Plasma Cell|Prostate Cancer|Multiple Myeloma|Breast Diseases|Lung Cancer|Myelodysplastic-Myeloproliferative Diseases |
2005-10-01 |
2024-11-27 |
Treatments |
|
| PCYC-0214 | P1 |
Completed |
Breast Cancer|Prostate Cancer |
None |
2019-03-21 |
Treatments |
|
| PCYC-0218 | P1 |
Completed |
Astrocytoma|Oligodendroglioma|Glioblastoma |
None |
2019-03-21 |
Treatments |
|
| PCYC-0212 | P1 |
Completed |
Breast Cancer|Gastrointestinal Cancer|Prostate Cancer |
None |
2019-03-21 |
Treatments |
|
| PCYC-0220 | P1 |
Completed |
Bronchogenic Carcinoma|Non-Small-Cell Lung Cancer |
None |
2019-03-21 |
Treatments |
|
| PCYC-0210 | P1 |
Terminated |
Head and Neck Cancer|Hypopharyngeal Cancer|Oropharyngeal Cancer|Squamous Cell Carcinoma|Laryngeal Cancer |
None |
2019-03-21 |
Treatments |
|
| PCYC-0227 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Adenocarcinoma |
2007-06-01 |
2019-03-21 |
Treatments |
|
| NCI-2009-01092 | P2 |
Completed |
Glioblastoma|Gliosarcoma |
2011-02-16 |
2019-03-21 |
||
| NCI-2012-01829 | P2 |
Completed |
Glioma |
2010-04-01 |
2019-03-22 |
Treatments |
|
| PCYC-0222 | P2 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Chronic Lymphoid Leukemia |
2010-02-01 |
2019-03-21 |
Treatments |
|
| PCYC-0229 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-02-01 |
2019-03-21 |
Treatments |
|
| PCYC-0228 | P2 |
Terminated |
Non-Small-Cell Lung Cancer |
2008-01-01 |
2019-03-21 |
Treatments |
|
| PCYC-0223 | P2 |
Completed |
Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia |
2007-02-01 |
2019-03-21 |
Treatments |
|
| NU 02H8 | P2 |
Terminated |
Lymphoma, Non-Hodgkin |
2007-01-01 |
2019-08-18 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
|
| MSKCC-01051 | P2 |
Completed |
Brain Stem Cancer|Glioblastoma |
2003-04-01 |
2019-03-21 |
||
| PCYC-0219 | P2 |
Completed |
Renal Cell Carcinoma |
None |
2019-03-21 |
Treatments |
|
| PCYC-0215 | P2 |
Completed |
Multiple Myeloma |
None |
2019-03-21 |
Treatments |
|
| PCYC-0224 | P2 |
Terminated |
Melanoma|Brain Cancer|Breast Cancer |
None |
2019-03-21 |
Treatments |
|
| PCYC-0221 | P2 |
Completed |
Lymphoma, Non-Hodgkin |
None |
2019-03-21 |
Treatments |
|
| PCYC-0216 | P2 |
Terminated |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
None |
2019-03-21 |
||
| SMART | P3 |
Completed |
Non-Small-Cell Lung Cancer|Brain Cancer |
None |
2019-03-21 |
Treatments |